EyePoint (EYPT) Asset Writedowns and Impairment (2011 - 2023)

EyePoint (EYPT) posted Asset Writedowns and Impairment of $533000.0 for Q2 2023, down 97.43% sequentially from $20.7 million in Q4 2022.

Analysis

EyePoint (EYPT) Asset Writedowns and Impairment (2011 - 2023) Analysis & Trends

EyePoint has reported Asset Writedowns and Impairment for 3 years, with the latest figure at $533000.0 in Q2 2023.

Quarterly Asset Writedowns and Impairment changed N/A year-over-year to $533000.0 in Q2 2023, while the trailing twelve-month figure through Sep 2024 was $533000.0 (down 97.49% YoY) and the FY2023 annual result came in at $693000.0, down 96.65% from the prior year.
Asset Writedowns and Impairment retreated to $533000.0 in Q2 2023 per EYPT's latest filing, from $20.7 million in the prior quarter.
Over five years, Asset Writedowns and Impairment peaked at $20.7 million in Q4 2022 and troughed at $533000.0 in Q2 2023.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	138.47 Bn	130.62 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.18 Bn	77.19 Bn	3.93 Bn
3	Argenx Se	63.38 Bn	58.19 Bn	1.37 Bn
4	Moderna	58.09 Bn	52.95 Bn	52.00 Mn
5	Revolution Medicines	44.33 Bn	44.33 Bn	-
6	BeOne Medicines	40.02 Bn	34.92 Bn	1.53 Bn
7	Alnylam Pharmaceuticals	35.57 Bn	32.27 Bn	992.69 Mn
8	Royalty Pharma	28.45 Bn	27.61 Bn	-
9	Insmed	27.48 Bn	26.32 Bn	358.27 Mn
10	EyePoint	398.53 Mn	218.06 Mn	507,000.00

Historic Data

Download Data